Study Name:
A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Targeted Disease(s):
Lung Cancer
Purpose of Study:
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion
Study Dates:
January 2, 2026 - August 12, 2031
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Bristol Myers Squibb
Sponsors:
Bristol Myers Squibb
ClinicalTrails.gov Identifier:
NCT07063745
